Orchestra BioMed Holdings, Inc. (OBIO)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q3 Loss, Beats Revenue Estimates
Orchestra BioMed Holdings, Inc. (OBIO) came out with a quarterly loss of $0.4 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to a loss of $0.41 per share a year ago.
Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Orchestra BioMed Holdings, Inc. (OBIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Beats Revenue Estimates
Orchestra BioMed Holdings, Inc. (OBIO) came out with a quarterly loss of $0.5 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to a loss of $0.45 per share a year ago.
Orchestra BioMed Holdings, Inc. (OBIO) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Orchestra BioMed Holdings, Inc. ever had a stock split?
Orchestra BioMed Holdings, Inc. Profile
| Biotechnology Industry | Healthcare Sector | David P. Hochman CEO | NASDAQ (NMS) Exchange | 68572M106 CUSIP |
| US Country | 70 Employees | - Last Dividend | - Last Split | 4 Aug 2020 IPO Date |
Overview
Orchestra BioMed Holdings, Inc. is a notable entity operating within the biomedical innovation domain. The company, headquartered in New Hope, Pennsylvania, stands out for its development and integration of ground-breaking therapeutic solutions aimed at tackling some of the most pressing health issues today. Its operational strategy heavily relies on collaboration with industry giants, such as Medtronic, Inc. and Terumo Medical Corporation, serving to expedite the development and market launch of its pioneering technologies. The essence of Orchestra BioMed's endeavors lies in its commitment to advancing medical science and enhancing patient care through its innovative product lineup.
Products and Services
The company offers a variety of products and services designed to address significant medical challenges through cutting-edge biomedical technologies:
- BackBeat Cardiac Neuromodulation Therapy (CNT)
- Virtue Sirolimus AngioInfusion Balloon (SAB)
- FreeHold Devices
A flagship innovation, BackBeat CNT presents a novel approach to managing hypertension (HTN), particularly intended for patients who require a cardiac pacemaker. This therapy operates on the premise of neuromodulation, offering a non-pharmacological alternative that manipulates heart rhythms to regulate blood pressure effectively. Orchestra BioMed's collaboration with Medtronic, Inc. aims to foster the development and subsequent commercialization of BackBeat CNT, promising a brighter future for HTN management.
Another pioneering product, the Virtue SAB, targets atherosclerotic artery disease treatment. This technology combines drug delivery with balloon angioplasty to offer a dual therapy approach in treating coronary and peripheral artery diseases. The strategic partnership with Terumo Medical Corporation underscores the anticipated global impact of Virtue SAB by broadening its accessibility and use in clinical settings.
Orchestra BioMed's FreeHold suite encompasses an array of support tools and devices crafted for minimally invasive surgeries. While details on this product line are more generic, the implication is clear: Orchestra BioMed endeavors to improve surgical outcomes and patient recovery times through innovative device solutions. These tools reflect the company's broader commitment to advancing minimally invasive medical procedures.
Contact Information
